Chia Tai Tianqing Pharmaceutical Group Co., Ltd. $1177.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS44
PHASE 3 / 2-319
RECRUITING23
READOUTS ≤12 MONTHS18
READOUT SLIPPED >6 MO17%
Delay Index: of 23 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Chia Tai Tianqing Pharmaceutical Group Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TQ05105 Tablet NCT04944043 |
P1/2 | Active, not recruiting | Chronic Graft Versus Host Disease | 45 | 2023-06-30 (+12 mo) |
| Anlotinib hydrochloride capsules, Penpulimab injection NCT05862337 |
P3 | Recruiting | Hepatocellular Carcinoma | 480 | 2024-08 |
| Anlotinib hydrochloride capsule NCT04854668 |
P3 | Active, not recruiting | Metastatic Colorectal Cancer | 748 | 2024-12-31 |
| 6.0 mg/kg of TQB2102 for injection NCT06198751 |
P2 | Active, not recruiting | Breast Cancer | 104 | 2025-05-08 (+4 mo) |
| TQB3616 capsule NCT05365178 |
P3 | Active, not recruiting | HR-positive, HER2-negative Breast Neoplasms | 432 | 2025-07-02 (+13 mo) |
| TQB3909 Tablets + Azacitidine NCT07011186 |
P1/2 | Recruiting | Myeloid Malignancy | 138 | 2025-10 |
| TQA3605 tablets NCT06150014 |
P1/2 | Active, not recruiting | Chronic Hepatitis b | 88 | 2025-12 |
| TQA3334 Tablet NCT06706310 |
P2 | Active, not recruiting | Chronic Hepatitis B | 116 | 2025-12-07 |
| TQB3702 tablets+Chemotherapy regimen NCT06566586 |
P2 | Recruiting | B-cell Lymphoma | 80 | 2026-03 |
| TQB2825 injection +R-CHOP regimen NCT06829771 |
P1/2 | Recruiting | Diffuse Large B Cell Lymphoma | 90 | 2026-05 (+2 mo) |
| TQB2916 injection + doxorubicin hydrochloride for injection NCT06500091 |
P2 | Not yet recruiting | Soft Tissue Sarcoma; Melanoma | 54 | 2026-06 |
| TQB3616 capsule+Fulvestrant Injection NCT06702618 |
P2 | Active, not recruiting | Breast Cancer | 33 | 2026-06 (+1 mo) |
| TQB2450 injection + Chemotherapy NCT05913089 |
P2 | Recruiting | Non Small Cell Lung Cancer | 58 | 2026-06 |
| D-1553 Tablet NCT06300177 |
P3 | Recruiting | Non Small Cell Lung Cancer | 522 | 2026-10 |
| TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen NCT05780567 |
P3 | Active, not recruiting | Breast Cancer | 1946 | 2026-12 |
| TQB2930 for injection NCT06202261 |
P1/2 | Recruiting | Metastatic Breast Cancer; Recurrent Breast Cancer | 154 | 2026-12 |
| TQ05105 Tablets NCT06122831 |
P1/2 | Recruiting | Myelofibrosis | 92 | 2026-12 |
| TQB3454 tablets NCT05987358 |
P3 | Active, not recruiting | Biliary Carcinoma | 165 | 2026-12 |
| TQB3702 Tablets NCT06859931 |
P2 | Not yet recruiting | Systemic Lupus Erythematosus | 120 | 2026-12 |
| AK105 Injection NCT04344158 |
P3 | Active, not recruiting | Advanced Hepatocellular Carcinoma (HCC) | 648 | 2026-12 (+29 mo) |
| TQB2102 for Injection NCT06561607 |
P3 | Active, not recruiting | Breast Cancer | 542 | 2027-01 |
| AL2846 Capsules NCT06860971 |
P3 | Recruiting | Thyroid Cancer | 144 | 2027-01 |
| TQB6411 Injection NCT07367516 |
P1/2 | Recruiting | Esophageal Cancer | 105 | 2027-02 |
| TQC3721 Suspension for Inhalation NCT07464587 |
P3 | Recruiting | Chronic Obstructive Pulmonary Disease | 800 | 2027-02 |
| TQC3721 Suspension for inhalation NCT07147946 |
P3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 666 | 2027-03 |
| TQB3473 Tablets NCT06900920 |
P3 | Recruiting | Primary Immune Thrombocytopenia | 199 | 2027-03 |
| TQB3201 tablets NCT07172126 |
P1/2 | Not yet recruiting | Metastatic Castration-resistant Prostate Cancer | 291 | 2027-04 |
| Angiotensin II Injection NCT06351150 |
P3 | Recruiting | Vasodilatory Shock | 214 | 2027-06 |
| TQD3524 NCT07512596 |
P2 | Recruiting | Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | 48 | 2027-07 |
| TQB3473 Tablets NCT07083739 |
P2 | Not yet recruiting | Primary Immune Thrombocytopenia | 320 | 2027-09 |
| TQH3906 capsule NCT07509892 |
P2 | Recruiting | Systemic Lupus Erythematosus | 198 | 2027-11 |
| TQ05105 tablets NCT06300320 |
P2 | Recruiting | Chronic Graft Versus Host Disease | 65 | 2027-11 (+25 mo) |
| LM-108 injection NCT06821503 |
P1/2 | Recruiting | Advanced Pancreatic Cancer | 72 | 2027-12 |
| Anlotinib hydrochloride capsule + TQB2450 injection NCT06475599 |
P3 | Not yet recruiting | Endometrial Cancer | 420 | 2027-12 |
| TQ-B3234 capsules NCT07407803 |
P3 | Recruiting | Plexiform Neurofibroma | 177 | 2027-12 |
| TQ05105 Tablets (Rovadicitinib Tablets) NCT07551427 |
P2 | Recruiting | Myelofibrosis | 51 | 2028-06 |
| TQA3605 tablets NCT07797231 |
P3 | Not yet recruiting | Chronic Hepatitis B | 930 | 2028-09 |
| TQB6411 for Injection NCT07367529 |
P1/2 | Recruiting | Advanced Lung Cancer | 465 | 2028-12 |
| TQB2934 injection NCT07569757 |
P3 | Not yet recruiting | Multiple Myeloma | 260 | 2028-12 |
| Benmelstobart injection combined with Anlotinib hydrochloride capsule NCT07548177 |
P2 | Recruiting | Alveolar Soft Part Sarcoma | 33 | 2028-12 |
| TQB3454 tablets NCT07738679 |
P2 | Not yet recruiting | Advanced Solid Tumors | 127 | 2028-12 |
| TQB3126 NCT07697443 |
P1/2 | Recruiting | Breast Cancer | 300 | 2029-08 |
| Rovadicitinib NCT06682169 |
P3 | Recruiting | Graft-versus-host Disease | 182 | 2029-10 |
| TQB3909 Tablets NCT07753369 |
P3 | Not yet recruiting | Small Lymphocytic Lymppho; Relapsed/Refractory Chronic Lymphocytic Leukemia | 128 | 2030-12 |